{"id":"dopamine-administration","safety":{"commonSideEffects":[{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Arrhythmias"},{"rate":null,"effect":"Vasoconstriction"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dopamine is a catecholamine neurotransmitter that binds to dopamine receptors (D1-D5) to modulate motor control, motivation, reward, and cardiovascular function. When administered exogenously, dopamine crosses the blood-brain barrier minimally due to its polar structure, making it primarily useful for peripheral effects on heart rate, blood pressure, and renal perfusion via D1 and β-adrenergic receptor activation.","oneSentence":"Dopamine administration directly replaces or supplements dopamine, a neurotransmitter that activates dopamine receptors in the central and peripheral nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:55.730Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypotension and shock (cardiogenic, septic, hypovolemic)"},{"name":"Heart failure with reduced cardiac output"},{"name":"Acute kidney injury with oliguria"}]},"trialDetails":[{"nctId":"NCT06687837","phase":"PHASE1","title":"Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons","status":"RECRUITING","sponsor":"Jeffrey S. Schweitzer, MD, PhD","startDate":"2025-04-29","conditions":"Parkinson Disease","enrollment":8},{"nctId":"NCT07484217","phase":"PHASE3","title":"Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","startDate":"2026-02-23","conditions":"Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms","enrollment":508},{"nctId":"NCT05909267","phase":"NA","title":"Dopamine Modulation of Motivation and Motor Function in Major Depression & Inflammation","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2023-07-26","conditions":"Depressive Disorder, Major","enrollment":165},{"nctId":"NCT04732065","phase":"PHASE1","title":"ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors","status":"RECRUITING","sponsor":"Sabine Mueller, MD, PhD","startDate":"2021-08-23","conditions":"Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma","enrollment":208},{"nctId":"NCT03537794","phase":"","title":"Characterizing Dopamine Receptor Binding in Treatment Resistant Depression","status":"RECRUITING","sponsor":"Unity Health Toronto","startDate":"2025-08-22","conditions":"Treatment Resistant Depression","enrollment":45},{"nctId":"NCT03947216","phase":"PHASE2","title":"Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-10-23","conditions":"Parkinson Disease","enrollment":117},{"nctId":"NCT07151378","phase":"PHASE3","title":"Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-10-27","conditions":"PARKINSON DISEASE (Disorder)","enrollment":150},{"nctId":"NCT07451561","phase":"NA","title":"Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03","conditions":"Acute Aluminum Phosphide Poisoned Cases","enrollment":74},{"nctId":"NCT06295952","phase":"PHASE2","title":"A Study of Pasireotide in People With Prolactinoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-02-27","conditions":"Prolactin-Producing Pituitary Tumor","enrollment":10},{"nctId":"NCT04735172","phase":"NA","title":"Exploration of Differences in Metabolite Concentrations by 7Teslas NMR Spectroscopy in Striatum and Subthalamic Nuclei in de Novo Parkinsonian Patients and Control Subjects","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2022-04-07","conditions":"Parkinson's Disease","enrollment":44},{"nctId":"NCT07423546","phase":"PHASE1, PHASE2","title":"A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2026-04-01","conditions":"SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder","enrollment":12},{"nctId":"NCT07218952","phase":"NA","title":"Radiation Therapy (RT) for Parkinson's Disease (PD)","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2026-04","conditions":"Parkinson's Disease","enrollment":20},{"nctId":"NCT01432821","phase":"NA","title":"Blinking and Yawning in Epilepsy: The Role of Dopamine","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2011-09","conditions":"Idiopathic Generalized Epilepsy","enrollment":31},{"nctId":"NCT07400731","phase":"NA","title":"Short and Long-term Responses of PD Symptoms to Earstim","status":"NOT_YET_RECRUITING","sponsor":"Stoparkinson Healthcare Systems LLC","startDate":"2026-02","conditions":"PARKINSON DISEASE (Disorder)","enrollment":90},{"nctId":"NCT07402928","phase":"","title":"Optimistic and Pessimistic Dopamine Signals in the Human Brain: a Mapping and Modelling Study in Health and Parkinson's Disease","status":"RECRUITING","sponsor":"Danish Research Centre for Magnetic Resonance","startDate":"2025-06-02","conditions":"Healthy, Parkinson, Medication Administration","enrollment":140},{"nctId":"NCT07322133","phase":"PHASE4","title":"Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2026-06-01","conditions":"Hypotension and Shock, Pulmonary Hypertension of the Newborn (PPHN), Hypoxemic Respiratory Failure","enrollment":30},{"nctId":"NCT05110157","phase":"PHASE3","title":"Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2021-11-29","conditions":"Schizophrenia","enrollment":442},{"nctId":"NCT07397247","phase":"NA","title":"Tonic Motor Activation (TOMAC) Therapy in Patients With Restless Legs Syndrome and Dopaminergic Augmentation","status":"NOT_YET_RECRUITING","sponsor":"Noctrix Health, Inc.","startDate":"2026-04","conditions":"Restless Legs Syndrome","enrollment":50},{"nctId":"NCT05824767","phase":"PHASE4","title":"Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2023-04-17","conditions":"Septic Shock, Vasodilatory Shock","enrollment":40},{"nctId":"NCT06484075","phase":"PHASE1, PHASE2","title":"Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms","status":"RECRUITING","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2024-11-21","conditions":"Healthy Volunteers, Alcohol Use Disorder (AUD)","enrollment":180},{"nctId":"NCT01239550","phase":"NA","title":"Insulin Detemir in Obesity Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University","startDate":"2011-04","conditions":"Diabetes, Obesity","enrollment":240},{"nctId":"NCT06937476","phase":"NA","title":"Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole","status":"RECRUITING","sponsor":"Central South University","startDate":"2025-05-08","conditions":"Major Depressive Disorder (MDD), Rumination","enrollment":108},{"nctId":"NCT07313176","phase":"","title":"Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease","status":"RECRUITING","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2026-01","conditions":"Advanced Parkinson Disease","enrollment":215},{"nctId":"NCT06785298","phase":"PHASE2, PHASE3","title":"Fexofenadine as Adjuvant Therapy in Parkinson Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-12-10","conditions":"Parkinson Disease","enrollment":46},{"nctId":"NCT03190954","phase":"EARLY_PHASE1","title":"Brain Dopaminergic Signaling in Opioid Use Disorders","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2017-08-17","conditions":"Normal Physiology, Opioid Use Disorders","enrollment":153},{"nctId":"NCT01626859","phase":"PHASE2, PHASE3","title":"A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":38},{"nctId":"NCT06498349","phase":"NA","title":"Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl","status":"RECRUITING","sponsor":"University of Kiel","startDate":"2024-09-05","conditions":"Parkinson Disease, Impulse Control Disorders","enrollment":60},{"nctId":"NCT02220309","phase":"","title":"Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-08-11","conditions":"Anxiety, Depression","enrollment":167},{"nctId":"NCT01626872","phase":"PHASE2, PHASE3","title":"Long-Term Study of MP-214 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-09","conditions":"Schizophrenia","enrollment":254},{"nctId":"NCT07297368","phase":"NA","title":"Enhanced Tai Chi for Parkinson's Disease (Enhanced Tai Chi PD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2024-05-01","conditions":"Parkinson Disease (PD)","enrollment":30},{"nctId":"NCT07166757","phase":"PHASE1, PHASE2","title":"Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease","status":"RECRUITING","sponsor":"XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.","startDate":"2025-09-22","conditions":"Parkinson Disease (PD)","enrollment":90},{"nctId":"NCT05318924","phase":"PHASE1, PHASE2","title":"Effects of Ghrelin Administration on Dopamine and Effort","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2022-02-21","conditions":"Major Depressive Disorder","enrollment":26},{"nctId":"NCT07289477","phase":"PHASE1","title":"A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy","status":"NOT_YET_RECRUITING","sponsor":"iRegene Therapeutics Co., Ltd.","startDate":"2025-12","conditions":"Multiple System Atrophy - Parkinsonian Subtype (MSA-P)","enrollment":9},{"nctId":"NCT05009992","phase":"PHASE2","title":"Combination Therapy for the Treatment of Diffuse Midline Gliomas","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-10-20","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma","enrollment":360},{"nctId":"NCT05635409","phase":"PHASE1","title":"A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Region Skane","startDate":"2022-11-30","conditions":"Parkinson Disease","enrollment":8},{"nctId":"NCT07273526","phase":"NA","title":"Adrenaline V/s Dopamine in Fuid Refractory Septic Shock","status":"RECRUITING","sponsor":"Laiba Qamar","startDate":"2025-06-01","conditions":"Fluid Refractory Septic Shock, Septic Shock","enrollment":90},{"nctId":"NCT07267065","phase":"PHASE1","title":"AAV2-hAADC for Parkinson's Disease (PDCS-01)","status":"NOT_YET_RECRUITING","sponsor":"Krzysztof Bankiewicz","startDate":"2026-02-01","conditions":"Parkinson's Disease (PD), Early Onset Parkinson Disease","enrollment":9},{"nctId":"NCT07213219","phase":"NA","title":"PET-MRI of Reward System in Parkinson's Disease With RBD","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2026-01-01","conditions":"Parkinson's Disease (PD)","enrollment":44},{"nctId":"NCT04228523","phase":"NA","title":"Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients? (ETPARK-REMED)","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2020-02-24","conditions":"Parkinson Disease","enrollment":24},{"nctId":"NCT07252752","phase":"NA","title":"Dopamine and Insulin in Psychosis","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Vienna","startDate":"2026-01-01","conditions":"First Episode Psychosis (FEP)","enrollment":46},{"nctId":"NCT05615220","phase":"PHASE3","title":"Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults","status":"COMPLETED","sponsor":"Emalex Biosciences Inc.","startDate":"2023-01-31","conditions":"Tourette Disorder","enrollment":216},{"nctId":"NCT06052787","phase":"PHASE3","title":"Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-09-01","conditions":"Traumatic Brain Injury","enrollment":150},{"nctId":"NCT07072910","phase":"PHASE2","title":"Cabergoline for Episodic Migraine","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-11-12","conditions":"Migraine","enrollment":150},{"nctId":"NCT04317807","phase":"PHASE2","title":"R33: Levetiracetam in Early Psychosis","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-08-27","conditions":"Early Psychosis","enrollment":65},{"nctId":"NCT06179108","phase":"PHASE2","title":"Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"LB Pharmaceuticals Inc.","startDate":"2023-11-29","conditions":"Schizophrenia","enrollment":359},{"nctId":"NCT05060549","phase":"PHASE4","title":"Dopamine D3 Receptor Occupancy in Bipolar Depression","status":"NOT_YET_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2026-01-06","conditions":"Bipolar Depression","enrollment":8},{"nctId":"NCT04457310","phase":"PHASE2","title":"A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-03-02","conditions":"Early Course Schizophrenia Spectrum Disorder","enrollment":112},{"nctId":"NCT07214285","phase":"PHASE1, PHASE2","title":"Evaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine)","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2025-10-01","conditions":"Parkinson Disease","enrollment":1},{"nctId":"NCT06611423","phase":"PHASE1","title":"AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2024-10-15","conditions":"Heart Failure With Reduced Ejection Fraction (HFrEF), Renal Impairment","enrollment":10},{"nctId":"NCT07045935","phase":"PHASE4","title":"Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-09-16","conditions":"Prolactinoma","enrollment":60},{"nctId":"NCT07175948","phase":"","title":"Outcome of Clinical Phenotypes of Pediatric Myocarditis at Assiut University Children Hospital","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-06-01","conditions":"Myocarditis, Myocarditis Acute","enrollment":100},{"nctId":"NCT07173738","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2018-06-11","conditions":"Pulmonary Arterial Hypertension","enrollment":44},{"nctId":"NCT06726785","phase":"","title":"Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment","status":"RECRUITING","sponsor":"HBC Immunology Inc","startDate":"2025-07-01","conditions":"Restless Leg Syndrome (RLS)","enrollment":50},{"nctId":"NCT07080775","phase":"PHASE1","title":"The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease","status":"RECRUITING","sponsor":"XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.","startDate":"2025-08-05","conditions":"Parkinson's Disease","enrollment":12},{"nctId":"NCT07001150","phase":"PHASE2","title":"Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-05-10","conditions":"Parkinson Disease","enrollment":50},{"nctId":"NCT06740812","phase":"PHASE4","title":"Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-05","conditions":"Nausea and Vomiting, Nausea, Vomiting","enrollment":212},{"nctId":"NCT04228276","phase":"NA","title":"Treating Stimulant Addiction With Repetitive Transcranial Magnetic Stimulation","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2021-02-05","conditions":"Stimulant Use Disorder, Substance-related Disorders","enrollment":30},{"nctId":"NCT04373317","phase":"PHASE4","title":"Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-10-24","conditions":"Parkinson's Disease Psychosis","enrollment":358},{"nctId":"NCT02169310","phase":"PHASE1","title":"Neural Basis of Decision-Making Deficits in Traumatic Brain Injury","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2014-11-18","conditions":"Traumatic Brain Injury","enrollment":45},{"nctId":"NCT06021522","phase":"PHASE3","title":"A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emalex Biosciences Inc.","startDate":"2023-08-16","conditions":"Tourette Syndrome","enrollment":150},{"nctId":"NCT07112105","phase":"NA","title":"Repetitive Transcranial Magnetic Stimulation Treatment of Stimulant Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-01-01","conditions":"Stimulant Use Disorder","enrollment":106},{"nctId":"NCT06978920","phase":"PHASE1","title":"A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease","status":"RECRUITING","sponsor":"Nuwacell Biotechnologies Co., Ltd.","startDate":"2025-06-06","conditions":"Parkinson Disease","enrollment":48},{"nctId":"NCT07096336","phase":"NA","title":"Effect of Vitamin D3 on Brain Waves in Male Parkinson's Patients With Low Vitamin D: A qEEG Study","status":"RECRUITING","sponsor":"Bangladesh Medical University","startDate":"2025-07-15","conditions":"PARKINSON DISEASE (Disorder)","enrollment":15},{"nctId":"NCT04459052","phase":"PHASE2","title":"FDOPA PET and Nutritional Support in Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2020-04-30","conditions":"Parkinson Disease, Idiopathic Parkinson Disease","enrollment":50},{"nctId":"NCT03295396","phase":"PHASE2","title":"ONC201 in Adults With Recurrent H3 K27M-mutant Glioma","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2017-10-30","conditions":"Glioma","enrollment":73},{"nctId":"NCT05636852","phase":"PHASE2","title":"Altropane Dose for Imaging Patients With Suspected Parkinson's Disease","status":"TERMINATED","sponsor":"GE Healthcare","startDate":"2023-04-24","conditions":"Parkinson Disease, Movement Disorders","enrollment":15},{"nctId":"NCT06333990","phase":"PHASE3","title":"Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)","status":"RECRUITING","sponsor":"Foundation for Advancing Veterans' Health Research","startDate":"2024-07-09","conditions":"Mild Traumatic Brain Injury","enrollment":146},{"nctId":"NCT06155812","phase":"PHASE2, PHASE3","title":"Multimodal Vasopressor Strategy in Septic Shock","status":"RECRUITING","sponsor":"University Medical Centre Maribor","startDate":"2023-12-23","conditions":"Shock, Septic","enrollment":80},{"nctId":"NCT05825235","phase":"PHASE3","title":"Long-term Efficacy of Pramipexole in Anhedonic Depression","status":"RECRUITING","sponsor":"Region Skane","startDate":"2023-04-21","conditions":"Anhedonia, Depression","enrollment":80},{"nctId":"NCT02339064","phase":"PHASE3","title":"Infusion of Apomorphine: Long-term Safety Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2015-02","conditions":"Idiopathic Parkinson's Disease","enrollment":99},{"nctId":"NCT02288962","phase":"PHASE3","title":"Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Olavs Hospital","startDate":"2014-11","conditions":"Pituitary Neoplasms, Adenoma","enrollment":60},{"nctId":"NCT04887467","phase":"PHASE4","title":"Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2021-09-16","conditions":"Parkinson Disease","enrollment":19},{"nctId":"NCT06808932","phase":"PHASE1","title":"VK4-116 Phase I Study With Food-Effect","status":"NOT_YET_RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2025-11-01","conditions":"Opioid Dependence, Opioid Use Disorder (OUD)","enrollment":48},{"nctId":"NCT05838430","phase":"PHASE4","title":"Solriamfetol and CBT-I in Patients With Insomnia Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-07-31","conditions":"Insomnia","enrollment":60},{"nctId":"NCT06967831","phase":"","title":"Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2020-03-01","conditions":"Leigh Syndrome (Maternally Inherited, MILS), Leigh Syndrome (AR, AD, XR)","enrollment":80},{"nctId":"NCT06951334","phase":"NA","title":"Clinical Trial of Vildagliptin in Early Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2025-06-01","conditions":"Parkinson's Disease","enrollment":66},{"nctId":"NCT06269146","phase":"PHASE2","title":"Pramipexole to Enhance Social Connections","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2024-05-13","conditions":"Anxiety Disorders, Anxiety, Depression","enrollment":108},{"nctId":"NCT04750070","phase":"PHASE3","title":"Management of Shock in Children With SAM or Severe Underweight and Diarrhea","status":"RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2021-08-17","conditions":"Shock Hypovolemic, Shock, Septic, Blood Transfusion","enrollment":135},{"nctId":"NCT06930261","phase":"PHASE2","title":"Dopaminergic Disruption Induced by Traumatic Coma: Dopaminergic Pathways Abnormalities and Biomarkers of Recovery Using MRI and 18F-LBT-999 PET","status":"RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2025-01-14","conditions":"Coma, Traumatic","enrollment":55},{"nctId":"NCT05119075","phase":"NA","title":"Psychological Effects of Levodopa in Parkinson's Disease","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2021-11-10","conditions":"Parkinson Disease","enrollment":23},{"nctId":"NCT05576818","phase":"PHASE3","title":"Effect of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2022-06-30","conditions":"Parkinson's Disease","enrollment":66},{"nctId":"NCT06237868","phase":"NA","title":"rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease","status":"RECRUITING","sponsor":"West Virginia University","startDate":"2024-05-01","conditions":"Impulse Control Disorder, Parkinson Disease","enrollment":20},{"nctId":"NCT05369533","phase":"PHASE1, PHASE2","title":"Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-08-01","conditions":"Stroke","enrollment":25},{"nctId":"NCT06855758","phase":"NA","title":"Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2025-03-06","conditions":"Kidney Transplant, Delayed Graft Function, Intraoperative Hypotension","enrollment":150},{"nctId":"NCT06880328","phase":"PHASE1","title":"18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-11-07","conditions":"Schizophrenia","enrollment":35},{"nctId":"NCT05140148","phase":"PHASE2","title":"Promoting Recovery After STroke With Amantadine","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-02-01","conditions":"Stroke, Ischemic, Stroke Hemorrhagic","enrollment":60},{"nctId":"NCT06586320","phase":"NA","title":"Quantification of Parkinson's Disease Patients As a Biomarker for Classification, Prediction and Response to Treatment","status":"ENROLLING_BY_INVITATION","sponsor":"Stardots AB","startDate":"2025-02-06","conditions":"Parkinson Disease","enrollment":40},{"nctId":"NCT06832358","phase":"NA","title":"Positive Psychological Intervention for Parkinson's Disease Patients","status":"COMPLETED","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2022-02-01","conditions":"Parkinson","enrollment":60},{"nctId":"NCT06688357","phase":"NA","title":"Revitalize Cognition: Near Infrared Stimulation in Parkinson Patients","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-06-26","conditions":"Parkinson Disease","enrollment":23},{"nctId":"NCT06702124","phase":"PHASE3","title":"A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease","status":"RECRUITING","sponsor":"I.R.C.C.S. Fondazione Santa Lucia","startDate":"2023-12-01","conditions":"Alzheimer Disease","enrollment":348},{"nctId":"NCT06754553","phase":"","title":"Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-02","conditions":"Parkinson Disease","enrollment":100},{"nctId":"NCT04038957","phase":"PHASE1","title":"A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-08-07","conditions":"Schizophrenia","enrollment":22},{"nctId":"NCT05184335","phase":"PHASE3","title":"Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia","status":"RECRUITING","sponsor":"Reviva Pharmaceuticals","startDate":"2022-01-24","conditions":"Schizophrenia","enrollment":690},{"nctId":"NCT05912543","phase":"NA","title":"A Titration of Fractional Inspired Oxygen Using Oxygen Reserve Index in Child","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2023-06-25","conditions":"Hyperoxemia","enrollment":70},{"nctId":"NCT01434251","phase":"NA","title":"Treatment of Hypotension of Prematurity (TOHOP)","status":"TERMINATED","sponsor":"UMC Utrecht","startDate":"2011-09-01","conditions":"Hypotension","enrollment":150},{"nctId":"NCT05385315","phase":"","title":"Towards the Validation of a New Blood Biomarker for the Early Diagnosis of Parkinson's Disease","status":"RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2022-10-13","conditions":"Parkinson Disease","enrollment":70},{"nctId":"NCT03562494","phase":"PHASE1","title":"VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2018-10-17","conditions":"Parkinson's Disease","enrollment":14},{"nctId":"NCT04789915","phase":"PHASE1","title":"Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis","status":"RECRUITING","sponsor":"Bjorn H. Ebdrup","startDate":"2021-05-26","conditions":"Psychosis, Negative Symptoms With Primary Psychotic Disorder","enrollment":46},{"nctId":"NCT04639960","phase":"NA","title":"Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome","status":"TERMINATED","sponsor":"University of Geneva, Switzerland","startDate":"2017-09-29","conditions":"22q11.2 Deletion Syndrome","enrollment":16},{"nctId":"NCT05585827","phase":"NA","title":"Online Cognitive Behavioral Therapy for Depressive Symptoms in Parkinson's Disease","status":"COMPLETED","sponsor":"Helse Stavanger HF","startDate":"2022-12-07","conditions":"Parkinson Disease, Depressive Symptoms, Anxiety","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":211,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dopamine administration","genericName":"Dopamine administration","companyName":"University of California, Davis","companyId":"university-of-california-davis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dopamine administration directly replaces or supplements dopamine, a neurotransmitter that activates dopamine receptors in the central and peripheral nervous system. Used for Hypotension and shock (cardiogenic, septic, hypovolemic), Heart failure with reduced cardiac output, Acute kidney injury with oliguria.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}